CA2680368A1 - A method of treating malignant mesothelioma - Google Patents

A method of treating malignant mesothelioma Download PDF

Info

Publication number
CA2680368A1
CA2680368A1 CA002680368A CA2680368A CA2680368A1 CA 2680368 A1 CA2680368 A1 CA 2680368A1 CA 002680368 A CA002680368 A CA 002680368A CA 2680368 A CA2680368 A CA 2680368A CA 2680368 A1 CA2680368 A1 CA 2680368A1
Authority
CA
Canada
Prior art keywords
cell
antibody
expression
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002680368A
Other languages
English (en)
French (fr)
Inventor
Chikao Morimoto
Kei Ohnuma
Teruo Inamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2680368A1 publication Critical patent/CA2680368A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002680368A 2007-03-14 2008-03-14 A method of treating malignant mesothelioma Abandoned CA2680368A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89478607P 2007-03-14 2007-03-14
US60/894,786 2007-03-14
PCT/JP2008/055344 WO2008114876A1 (en) 2007-03-14 2008-03-14 A method of treating malignant mesothelioma

Publications (1)

Publication Number Publication Date
CA2680368A1 true CA2680368A1 (en) 2008-09-25

Family

ID=39765975

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002680368A Abandoned CA2680368A1 (en) 2007-03-14 2008-03-14 A method of treating malignant mesothelioma

Country Status (5)

Country Link
US (2) US20100135993A1 (https=)
EP (1) EP2131863A4 (https=)
JP (1) JP4865868B2 (https=)
CA (1) CA2680368A1 (https=)
WO (1) WO2008114876A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2403877B1 (en) * 2009-03-06 2015-05-06 Klaus Tschira Stiftung GgmbH Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
US20120045435A1 (en) * 2010-08-18 2012-02-23 Theresa Deisher Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
JP6931228B2 (ja) * 2015-09-11 2021-09-01 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体と他の抗癌剤とを組み合わせた癌治療用組成物
US10282369B2 (en) * 2017-03-08 2019-05-07 Centri Technology, Inc. Fast indexing and searching of encoded documents
JP7064203B2 (ja) * 2018-03-16 2022-05-10 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体
WO2022066847A1 (en) * 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
KR20240007229A (ko) * 2021-05-13 2024-01-16 아디에네 에스.에이. 이식편 대 숙주 질환을 치료하는 방법
US20250340665A1 (en) 2021-05-13 2025-11-06 Adienne S.A. Methods of treating dermatomyositis
WO2022255248A1 (ja) * 2021-05-31 2022-12-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
CN116023491A (zh) * 2021-10-25 2023-04-28 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其应用
CN116549629A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863624B1 (ko) * 2001-05-11 2008-10-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체
US20030138429A1 (en) * 2001-05-22 2003-07-24 Pizzo Salvatore V. Compositions and methods for inhibiting metastasis
EP1907425B1 (en) * 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anti-cd26 antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP4865868B2 (ja) 2012-02-01
EP2131863A4 (en) 2012-07-11
US20140004103A1 (en) 2014-01-02
WO2008114876A1 (en) 2008-09-25
JP2010521418A (ja) 2010-06-24
US8771688B2 (en) 2014-07-08
US20100135993A1 (en) 2010-06-03
EP2131863A1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
US8771688B2 (en) Method of treating malignant mesothelioma
CN103275227B (zh) Axl抗体
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
JP6670248B2 (ja) 抗ｃｄ３８抗体との併用療法
CN106456731B (zh) 用于治疗急性成淋巴细胞性白血病的抗cd38抗体
JP4464450B2 (ja) インスリン様増殖因子ｉ受容体に対する抗体およびその使用
RU2571224C2 (ru) Гуманизированные антитела против axl
EP1907425B1 (en) Anti-cd26 antibodies and methods of use thereof
US20110165161A1 (en) Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
TW201934580A (zh) 對cd70具特異性抗體及其用途
CA2670039A1 (en) Novel antiproliferation antibodies
JPWO2016133059A1 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
CN101528256B (zh) 抗-cd151抗体在治疗癌症中的用途
RU2801093C2 (ru) Антитела, специфические в отношении cd70, и пути их применения
US20150152193A1 (en) Axl antibodies
HK1132904B (en) Use of an anti-cd151 antibody in the treatment of cancer
MX2008000884A (en) Anti-cd26 antibodies and methods of use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140314